Kindred Biosciences (KIN) 4.20 $KIN Kindred Biosciences

New Post Public Reply Private Reply Replies (0) Message Board

Sep 3, 2016 at 3:08 PM

Kindred Biosciences (KIN) 4.20 $KIN

Kindred Biosciences (KIN) Jumps: Stock Moves 5.7% Higher
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:15AM CDT
Kindred Biosciences, Inc. (KIN) shares rose almost 6% in the last trading session.
ANIP: 59.86 (-1.56), KIN: 4.20 (+0.05)

Kindred Biosciences Submits New Animal Drug Application Technical Section for Effectiveness for Mirataz to FDA
PR Newswire - Mon Aug 22, 3:01PM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission of the Effectiveness Technical Section of the New Animal Drug Application for Mirataz(TM) (mirtazapine transdermal ointment) to the Food and Drug Administration (FDA) for the management of weight loss in cats. The Chemistry, Manufacturing, and Controls Technical Section was submitted in May 2016 and the Company plans to submit the Safety Technical Section in the third quarter of 2016.
KIN: 4.20 (+0.05)

Kindred Biosciences Announces Second Quarter 2016 Financial Results
PR Newswire - Mon Aug 08, 3:01PM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the second quarter ended June 30, 2016 and provided updates on its programs.
KIN: 4.20 (+0.05)

Kindred Biosciences Announces HITS Sponsorship
PR Newswire - Wed May 25, 3:05PM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, is pleased to announce their Platinum Sponsorship of the HITS Horse Show series. The sponsorship will start this week at the Saugerties, New York facility for the HITS-on-the-Hudson series and will extend through both the HITS Ocala Winter Circuit in Ocala, Florida, and the HITS Desert Circuit in Thermal, California.
KIN: 4.20 (+0.05)

Kindred Biosciences Announces Positive Results from Pivotal Study of KIND-010 for the Management of Weight Loss in Cats
PR Newswire - Mon May 16, 7:30AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pivotal field study of KIND-010, mirtazapine transdermal gel, for the management of weight loss in cats.
KIN: 4.20 (+0.05)

Kindred Bio reports 1Q loss
Automated Insights - Thu May 05, 7:56AM CDT
BURLINGAME, Calif. (AP) _ Kindred Biosciences Inc. (KIN) on Thursday reported a loss of $6.1 million in its first quarter.
KIN: 4.20 (+0.05)

Kindred Biosciences Announces First Quarter 2016 Financial Results
PR Newswire - Thu May 05, 7:30AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2016 and provided updates on its programs.
KIN: 4.20 (+0.05)

Kindred Biosciences Submits KIND-010 New Animal Drug Application Technical Section for Chemistry, Manufacturing, and Controls to FDA
PR Newswire - Wed May 04, 3:02PM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Chemistry, Manufacturing, and Controls (CMC) technical section of the New Animal Drug Application for KIND-010.
KIN: 4.20 (+0.05)

Kindred Biosciences to Announce First Quarter 2016 Financial Results
PR Newswire - Mon Apr 25, 8:02AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its first quarter 2016 financial results on May 5, 2016 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day.
KIN: 4.20 (+0.05)

Kindred Biosciences Elects Herbert D. Montgomery to Join Its Board of Directors
PR Newswire - Fri Apr 15, 8:02AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Mr. Herbert Montgomery will be joining the Company's Board of Directors. Mr. Montgomery will serve as the Chairman of the Company's Audit Committee.
KIN: 4.20 (+0.05)

The Zacks Analyst Blog Highlights: Actelion, Mesoblast, Kindred Biosciences and CorMedix
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 8:30AM CDT
The Zacks Analyst Blog Highlights: Actelion, Mesoblast, Kindred Biosciences and CorMedix
CRMD: 1.83 (-0.08), MESO: 4.96 (unch), KIN: 4.20 (+0.05)

4 Best Biotech Stocks of the First Quarter of 2016
Zacks Equity Research - Zacks Investment Research - Fri Apr 01, 9:03AM CDT
Don't miss these best biotech stocks of the first quarter of 2016.
CRMD: 1.83 (-0.08), MESO: 4.96 (unch), GILD: 76.89 (-0.53), SHPG: 192.37 (+3.87), AMGN: 169.77 (-0.36), BXLT: 46.02 (-0.18), KIN: 4.20 (+0.05)

Kindred Biosciences Releases Positive Results of Pilot Field Study of KIND-010 for the Management of Weight in Cats
PR Newswire - Tue Jan 26, 8:02AM CST
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today released positive results from its pilot field study (KB104P) of KIND-010 for the management of weight in cats. It also announced successful completion of the sample size reassessment of the ongoing pivotal study.
KIN: 4.20 (+0.05)

Kindred Biosciences to Provide Corporate Update
PR Newswire - Thu Jan 07, 8:02AM CST
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will provide a corporate update via webcast on Monday, January 11, 2016 in advance of one-on-one investor meetings in San Francisco January 12-14, 2016.
KIN: 4.20 (+0.05)

Kindred Biosciences submits NADA's CMC to US FDA for KIND-012
M2 - Fri Dec 18, 5:12AM CST
Biopharmaceutical company Kindred Biosciences (NasdaqCM:KIN) said on Thursday that it has submitted the Chemistry, Manufacturing and Controls (CMC) technical section of the New Animal Drug Application (NADA) for KIND-012 to the US FDA.
KIN: 4.20 (+0.05)

A Look Inside the Chart, Technical Insights - Research on Westbury Bancorp, FalconStor Software, Kindred Biosciences and Connecture
ACCESSWIRE - Thu Dec 03, 8:02AM CST
NEW YORK, NY / ACCESSWIRE / December 3, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Westbury Bancorp Inc. (NASDAQ: WBB), FalconStor Software Inc. (NASDAQ: FALC), Kindred Biosciences Inc. (NASDAQ: KIN) and Connecture Inc. (NASDAQ: CNXR). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
CNXR: 1.69 (+0.02), FALC: 1.02 (unch), WBB: 19.25 (-0.35), KIN: 4.20 (+0.05)

Kindred Biosciences (KIN) Is in Oversold Territory: What's Next?
Zacks Equity Research - Zacks Investment Research - Thu Oct 01, 7:27AM CDT
Kindred Biosciences (KIN) Is in Oversold Territory: What's Next?
KIN: 4.20 (+0.05)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Xylem Investigation: Legal Drama Unfolds for Investors

Riding the Waves of Xylem's Share Shocks Xylem Inc. put shareholders on a dizzying rollercoaster, adjusting its earnings expectations in a way that’s left plenty of investors fuming. Back in July, the company hyped up its 2026 earnings outlook, only to slash it three months later in October. For folks holding bags of NYSE:XYL, this abrupt shift is more than a numbers...

FuelCell Energy Faces Legal Scrutiny After Stock Plunge

FuelCell Energy's Troubling Stock Dive FuelCell Energy's recent plummet isn't just a sobering reality for traders—it comes wrapped in controversy. With NASDAQ:FCEL suffering a 15.69% nosedive after revelations from their fiscal third-quarter results, the ticker’s future hangs precariously. Even for those who've braved the market’s caprices, seeing shares drop $2.68...

Landis+Gyr's Q2 Gains and Future Strategies

Landis+Gyr's Multi-Faceted Financial Leap In the unpredictable landscape of energy tech, Landis+Gyr has thrown down some noteworthy cards in their latest financial disclosures. We're talking a Q2 net revenue sitting pretty at $269.2 million, and it's no mistake they landed a record-smashing adjusted gross margin of 38.0%. All this while wrangling an order intake of $170.3...

ID Plans Secures Polaris Investment for Real Estate Boost

New Moves in Real Estate Tech Can you smell opportunity? Because it’s in the air down in Tampa where ID Plans just inked a deal with Polaris Growth Fund. We’re talking some serious private equity backing here aimed at ramping up what ID Plans can lay down in the commercial real estate sector. If you're not on this ride yet, it might be time to take a closer look....

Mausam Bhatt Joins Cars.com as Chief Product Officer

Shifting Gears with a New Leader Sometimes the name alone isn't enough to get things rolling, but when someone who's built billion-dollar platforms from scratch joins your team, the engine's ready to roar. That's the motor firing up at Cars.com with Mausam Bhatt behind the wheel as their fresh Chief Product Officer. If you think a new set of eyes can only see what's...

Aker BP's Q3 2026: Strong Earnings Fuel Optimism

Third Quarter Overview: Riding the Wave Aker BP's third quarter report is a raucous symphony of successes that have the market nodding in admiration. Marking significant strides with their offshore projects, the company seems to be in a cavalier mood as it boasts higher sales volumes and promising financials. Net production came in at 374 mboepd, dampened slightly by...

Digital Science's Game-Changing Jenni AI Acquisition

A Strategic Move in the Research Sector When you're dealing with tech giants and their endless race to corner niche markets, it's the big moves that really catch one's attention. The latest acquisition on the block is Digital Science picking up Jenni AI, a platform trusted by over 8 million students and researchers scattered across 189 countries. Now, that's a hefty user...

Unpacking NOMMA's Unique Blend of Education Strategies

Introducing NOMMA's Unique Approach Well, here’s one for the books—an educational model that smacks of good ol’ discipline and sharpens minds for what's beyond the classroom. Located in New Orleans, the Military and Maritime Academy, or NOMMA if you want to keep things snappy, serves up an education with a difference. Not only does it prepare cadets academically,...

Dermatology Access Expands in Kansas With Expert Return

Jenna King's Return Elevates Local Care Who says you can't go home again? Jenna King, a familiar face in Southeast Kansas, is back to serve her community by upping the ante in dermatology care at U.S. Dermatology Partners in Pittsburg. After gaining experience in Oklahoma, she's here to extend both medical and cosmetic treatments to her neighbors. Why Her Return Is a Game...

Busch Gardens' Holiday Extravaganza Lights Up 2026

A Dazzling Holiday Transformation Awaits Forget the mundane holiday light displays. Busch Gardens is cranking it up a notch with their annual Christmas Town spectacle, kicking off on November 13. With two parks—Tampa Bay and Williamsburg—each delivering a unique experience, prepare for an immersive dive into holiday cheer that's packed with glitz, entertainment, and,...